Credit Suisse analyst Jason Kantor reiterated an Outperform rating and boosted his price target on PTC Therapeutics (NASDAQ: PTCT) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE